Indications for mexiletine in the new ESC guidelines and beyond

References

• Wilde AA, Langendijk P. Antiarrhythmic drugs, patients, and the pharmaceutical industry: value for patients, physicians, pharmacists or shareholders? Neth Heart J. 2007;15(4):127–128. doi: 10.1007/BF03085967
   PubMed Web of Science ®Google Scholar
• Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018;138:p. e272–e391.
   Google Scholar
• Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43:3997–4126. doi: 10.1093/eurheartj/ehac262
   PubMed Web of Science ®Google Scholar
• van der Ree MH, van Dussen L, Rosenberg N, et al. Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review. Europace. 2022 Nov 22;24:1809–1823. doi: 10.1093/europace/euac087
   PubMed Web of Science ®Google Scholar
• Ali H, Cristiano E, Lupo P, et al. Oral mexiletine for ventricular tachyarrhythmias treatment in implantable cardioverter-defibrillator patients: a systematic review of the literature. Minerva Cardiol Angiol. [2022 Oct 28]. Epub ahead of print. DOI:10.23736/S2724-5683.22.06176-2
   Google Scholar
• Brunton Laurence, Chabner Bruce, Knollman Bjorn. 2011 . Goodman and Gilman's The pharmacological basis of therapeutics. 12th ed.
   Google Scholar
• Lei M, Wu L, Terrar DA, et al. Modernized classification of cardiac antiarrhythmic drugs. Circulation. 2018;138(17):1879–1896. doi: 10.1161/CIRCULATIONAHA.118.035455
   PubMed Web of Science ®Google Scholar
• Stunnenberg BC, Raaphorst J, Groenewoud HM, et al. Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA. 2018;320(22):2344–2353. doi: 10.1001/jama.2018.18020
   PubMed Web of Science ®Google Scholar
• Carroll IR, Kaplan KM, Mackey SC. Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success. J Pain Symptom Manage. 2008;35(3):321–326. doi: 10.1016/j.jpainsymman.2007.04.022
   PubMed Web of Science ®Google Scholar
• Zehender M, Geibel A, Hust M, et al. Anti-arrhythmia effectiveness and tolerance of retard in comparison with standard mexiletine. Z Kardiol. 1987;76:501–506.
   PubMedGoogle Scholar
• Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13(8):1077–1109. doi: 10.1093/europace/eur245
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92:3381–3386. doi: 10.1161/01.CIR.92.12.3381
   PubMed Web of Science ®Google Scholar
• Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016;67(9):1053–1058. doi: 10.1016/j.jacc.2015.12.033
   PubMed Web of Science ®Google Scholar
• Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation. 2007;116(10):1137–1144. doi: 10.1161/CIRCULATIONAHA.107.707877
   PubMed Web of Science ®Google Scholar
• Zhu W, Mazzanti A, Voelker TL, et al. Predicting patient response to the antiarrhythmic mexiletine based on genetic variation. Circ Res. 2019;124(4):539–552. doi: 10.1161/CIRCRESAHA.118.314050
   PubMed Web of Science ®Google Scholar
• Li G, Woltz RL, Wang CY, et al. Gating properties of mutant sodium channels and responses to sodium current inhibitors predict mexiletine-sensitive mutations of long QT syndrome 3. Front Pharmacol. 2020;11:1182. doi: 10.3389/fphar.2020.01182
   PubMed Web of Science ®Google Scholar
• Bos JM, Crotti L, Rohatgi RK, et al. Mexiletine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome. Circ Arrhythm Electrophysiol. 2019;12:e007280. doi: 10.1161/CIRCEP.118.007280
   PubMed Web of Science ®Google Scholar
• Yang Y, Lv TT, Li SY, et al. Sodium channel blockers in the management of long QT syndrome types 3 and 2: a system review and meta-analysis. J Cardiovasc Electrophysiol. 2021;32(11):3057–3067. doi: 10.1111/jce.15223
   PubMed Web of Science ®Google Scholar
• Varian K, Tang WHW. Therapeutic strategies targeting inherited cardiomyopathies. Curr Heart Fail Rep. 2017;14(4):321–330. doi: 10.1007/s11897-017-0346-8
   PubMedGoogle Scholar
• Valdivia CR, Tester DJ, Rok BA, et al. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovasc Res. 2004;62(1):53–62. doi: 10.1016/j.cardiores.2004.01.022
   PubMed Web of Science ®Google Scholar
• Shen L, Jhund PS, Petrie MC, et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377(1):41–51. doi: 10.1056/NEJMoa1609758
   PubMed Web of Science ®Google Scholar
• Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111–121. doi: 10.1056/NEJMoa1513614
   PubMed Web of Science ®Google Scholar
• Deyell MW, Steinberg C, Doucette S, et al. Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. J Cardiovasc Electrophysiol. 2018;29(4):603–608. doi: 10.1111/jce.13431
   PubMed Web of Science ®Google Scholar
• Yano M, Nishida Y, Kai K, et al. Long QT syndrome in pregnancy: a successful case of ICD implantation during the prenatal period. J Obstet Gynaecol. 2017;37(4):531–532. doi: 10.1080/01443615.2017.1284771
   PubMedGoogle Scholar
• Lee MJ, Monteil DC, Spooner MT, et al. Peripartum management of patient with long QT3 after successful implantable cardioverter defibrillator device discharge resulting in device failure: a case report. Eur Heart J Case Rep. 2021;5(12):ytab487. doi: 10.1093/ehjcr/ytab487
   PubMedGoogle Scholar
• Timmis AD, Jackson G, Holt DW. Mexiletine for control of ventricular dysrhythmias in pregnancy. Lancet. 1980;2(8195pt1):647–648. doi: 10.1016/S0140-6736(80)90319-0
   PubMedGoogle Scholar
• Gregg AR, Tomich PG. Mexilitene use in pregnancy. J Perinatol. 1988;8(1):33–35.
   PubMedGoogle Scholar
• Lownes HE, Ives TJ. Mexiletine use in pregnancy and lactation. Am J Obstet Gynecol. 1987;157(2):446–447. doi: 10.1016/S0002-9378(87)80191-6
   PubMed Web of Science ®Google Scholar
• Monfort A, Morin C, Jutras M, et al. Transfer of mexiletine into breast milk: a case report. Breastfeed Med. Epub ahead of print. 2023 May 12. doi: 10.1089/bfm.2023.0042
   Web of Science ®Google Scholar
• Catalano A, Budriesi R, Bruno C, et al. Searching for new antiarrhythmic agents: evaluation of meta-hydroxymexiletine enantiomers. Eur J Med Chem. 2013 Jul;65:511–516.
   PubMed Web of Science ®Google Scholar
• Gualdani R, Tadini-Buoninsegni F, Roselli M, et al. Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine. Pharmacol Res Perspect. 2015 Oct;3(5):e00160.
   PubMedGoogle Scholar